Recombinant Human FGF basic represents the C-terminal protion of human fibroblast growth factor 2 (A135 - S288).
Fibroblast growth factor basic (FGF basic), also known as FGF 2, is a heparin binding growth factor which has stimulatory activity on a range of cells of mesenchymal, neuroectodermal and endothelial origin. Note: FGF basic is sensitive to acidic conditions.
Purified recombinant protein expressed in E. coli - lyophilised
Reconstitute with 0.5ml Tris (5mM, pH7.6). Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. Further dilutions may be prepared in a buffer containing a carrier protein (eg 0.1% BSA).
2 x 106 units/mg
>95% by SDS PAGE and HPLC analysis
Approx. Protein Concentrations
Total protein concentration 0.1 mg/ml after reconstitution.
Protein Molecular Weight
17.2kD (154 amino acid sequence)
Reagents In The Kit
Preparing The Antibody
TRIS buffered saline.
Prior to reconstitution store at +4oC. Following reconstitution store at -20oC.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Where this protein has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the protein for use in their own system using appropriate negative/positive controls.
This product may be used as a standard for ELISA applications with either AHP1038 or AHP1038B.
Histology Positive Control Tissue
This product may be used as the positive control for Wester Blot applications with either AHP1038 or AHP1038B.
1. Svendsen, C.N. et al. (1997) Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease.Exp Neurol. 148: 135-46.
2. Kim, T.H. et al. (2005) Recombinant human prothrombin kringle-2 induces bovine capillary endothelial cell cycle arrest at G0-G1 phase through inhibition of cyclin D1/CDK4 complex: modulation of reactive oxygen species generation and up-regulation of cyclin-dependent kinase inhibitors.Angiogenesis. 8: 307-14.
3. van Beuningen, HM et al. (2014) Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like conditions.Tissue Eng Part A. 20 (15-16): 2243-52.
4. Pleumeekers, M.M. et al. (2014) The in vitro and in vivo capacity of culture-expanded human cells from several sources encapsulated in alginate to form cartilage.Eur Cell Mater. 27: 264-80.
5. Willems, N. et al. (2015) Intradiscal application of rhBMP-7 does not induce regeneration in a canine model of spontaneous intervertebral disc degeneration.Arthritis Res Ther. 17: 137.
6. Pleumeekers, M.M. et al. (2015) Cartilage regeneration in the head and neck area: Combination of ear or nasal chondrocytes and mesenchymal stem cells improves cartilage production: Cell combinations for cartilage production.Plast Reconstr Surg. Aug 10. [Epub ahead of print]
7. Dimitrellos, V. et al. (2003) Capillary electrophoresis and enzyme solid phase assay for examining the purity of a synthetic heparin proteoglycan-like conjugate and identifying binding to basic fibroblast growth factor.Biomed Chromatogr. 17 (1): 42-7.
8. Narcisi R et al. (2015) Long-term expansion, enhanced chondrogenic potential, and suppression of endochondral ossification of adult human MSCs via WNT signaling modulation.Stem Cell Reports. 4 (3): 459-72.